Comparative Pharmacology
Head-to-head clinical analysis: ACCOLATE versus MONTELUKAST SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCOLATE versus MONTELUKAST SODIUM.
ACCOLATE vs MONTELUKAST SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective leukotriene receptor antagonist (LTRA) that inhibits the cysteinyl leukotriene (CysLT1) receptor, preventing bronchoconstriction, inflammation, and airway edema.
Selective leukotriene receptor antagonist that inhibits the actions of leukotriene D4 at the CysLT1 receptor, reducing bronchoconstriction, eosinophilic infiltration, mucus production, and airway remodeling.
20 mg orally twice daily, 1 hour before or 2 hours after meals.
10 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 10–20 hours (mean ~15 hours) in healthy adults; prolonged in hepatic impairment.
2.7–5.5 hours in healthy adults; prolonged to 7.4 hours in hepatic impairment (Child-Pugh score 5–9).
Primarily hepatic metabolism via CYP2C9; 87% excreted in feces, 10% in urine as metabolites. Less than 1% excreted unchanged.
Fecal (86%) and renal (<0.2% as unchanged drug); primarily biliary excretion of metabolites.
Category C
Category A/B
Leukotriene Receptor Antagonist
Leukotriene Receptor Antagonist